Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: Propensity score analysis

Table 2 Univariate analyses to identify predictors of overall survival among all patients in the cohort

Variable	n	Overall survival (%)			Log-rankP value
		1-yr	2-yr	3-yr
AFP, ng/mL
< 400	171	89.4	80.8	74.7	0.007
≥ 400	58	82.6	68.6	55.7
Tumor size, cm
≤ 5	93	96.8	92.1	86.0	< 0.001
> 5	136	81.5	67.8	58.9
BCLC stage
A	168	89.3	80.1	74.2	0.020
B	61	83.4	70.7	59.1
Blood transfusion
Yes	55	76.4	66.7	54.9	0.030
No	174	91.3	81.1	74.3
Adjuvant TACE
Yes	91	93.4	86.4	79.2	0.012
No	138	84.1	71.9	63.7

AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer staging system; TACE: Transarterial chemoembolization.